New eye injection shows promise for rare Blindness-Causing gene mutation
NCT ID NCT06455826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a new drug called VP-001, given as an injection into the eye, for people with a rare genetic eye disease (PRPF31 mutation) that causes vision loss. Six participants aged 12 and older received multiple doses. The main goal was to check for side effects, not to measure vision improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine- Alkek Eye Center
Houston, Texas, 77030, United States
-
Oregon Health and Science University - Casey Eye Institute
Portland, Oregon, 97239, United States
-
Retina Foundation of the Southwest
Dallas, Texas, 75321, United States
-
University of Florida Health
Jacksonville, Florida, 32209, United States
-
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smartphone camera spot blinding eye diseases?
- Could stem cells restore sight in damaged eyes?
- New eye scanner aims to sharpen view of retinal disease
- New eye camera could spot retinal disease earlier
- AI boosts eye Doctors' accuracy in reading retinal scans?
- 5,000 seniors join landmark eye health study to unlock secrets of aging vision